title: Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients.
abstract: BACKGROUND
  Aripiprazole is a new antipsychotic agent that has proven safe and efficacious in controlled clinical trials. However, few published data on its effectiveness and safety when used in augmentation and combination are available.
  
  
  METHODS
  Our study aimed to determine the functional effectiveness and safety of different combinations of aripiprazole with other psychotropics in resistant patients. All acute not selected (15) patients treated with aripiprazole and other psychotropics between February 2005 and May 2007 are included.
  
  
  RESULTS
  Mean follow-up 20.4 days. Main diagnosis was schizophrenia (40%) and mean dose of aripiprazole was 25 mg/d. Resistant patients received initially multiple psychotropics (mean 3.3) and their functional status was very low. A significant functional improvement was observed after admission in most (12) of them. Only three patients experienced mild to moderate improvement; another three patients showed extrapyramidal symptoms. No dermatological reactions or adverse effects were observed with lamotrigine association. DISCUSIONS: The combination of aripiprazole with other psychotropics was well tolerated. No significant new adverse reactions were observed. In a short term follow-up, our results show a good tolerability of aripiprazole in combination with other psychotropics of different groups.
authors.affiliation: Salut Mental, Corporació Sanitària Parc Taulí. Sabadell, Barcelona, Spain. jcobo@tauli.cat
authors.forename: Jesús Vicente
authors.initials: JV
authors.lastname: Cobo Gómez
authors.forename: Jesús Vicente Cobo
authors.initials: JV
authors.lastname: Gómez
authors.forename: Gideoni
authors.initials: G
authors.lastname: Fuste
authors.forename: Ramón
authors.initials: R
authors.lastname: Coronas
authors.forename: Nagore
authors.initials: N
authors.lastname: Benito
authors.forename: Juan-David
authors.initials: JD
authors.lastname: Barbero
authors.forename: Cristina
authors.initials: C
authors.lastname: Domenech
authors.forename: Gemma
authors.initials: G
authors.lastname: García-Parés
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068180:Aripiprazole; D004351:Drug Resistance; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D017063:Outcome Assessment, Health Care; D010554:Personality Disorders / Q000188:drug therapy; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D013030:Spain
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D011619:Psychotropic Drugs; D015363:Quinolones; D000068180:Aripiprazole